Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anup K Amatya

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Neuropsychology|November 13, 2008
Deficits in complex motor functions, despite no evidence of procedural learning deficits, among HIV+ individuals with history of substance dependenceRaul Gonzalez, Joanna Jacobus, Anup K Amatya, et al.
Annual Review of Public Health|January 15, 2010
Post-approval drug safety surveillanceRobert D Gibbons, Anup K Amatya, C Hendricks Brown, et al.
Statistics in Medicine|April 12, 2008
Mixed-effects Poisson regression analysis of adverse event reports: the relationship between antidepressants and suicideRobert D Gibbons, Eisuke Segawa, George Karabatsos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2022
FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast CancerMirat Shah, Christy L Osgood, Anup K Amatya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2024
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract CancerSandra J Casak, Vaibhav Kumar, Chi Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
FDA Approval Summary: Tarlatamab for the Treatment of Extensive Stage Small Cell Lung CancerYufan Liu, Jeannette Nashed, Amy K Barone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2024
Improving Collection and Analysis of Overall Survival DataLisa R Rodriguez, Nicole J Gormley, Ruixiao Lu, et al.
The Oncologist|July 6, 2024
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutationsGautam U Mehta, Paz J Vellanki, Yi Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2023
FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade GliomaMichael I Barbato, Jeannette Nashed, Diana Bradford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2021
Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case ExamplesAnup K Amatya, Mallorie H Fiero, Erik W Bloomquist, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Neuropsychology|November 13, 2008
Deficits in complex motor functions, despite no evidence of procedural learning deficits, among HIV+ individuals with history of substance dependenceRaul Gonzalez, Joanna Jacobus, Anup K Amatya, et al.
Annual Review of Public Health|January 15, 2010
Post-approval drug safety surveillanceRobert D Gibbons, Anup K Amatya, C Hendricks Brown, et al.
Statistics in Medicine|April 12, 2008
Mixed-effects Poisson regression analysis of adverse event reports: the relationship between antidepressants and suicideRobert D Gibbons, Eisuke Segawa, George Karabatsos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2022
FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast CancerMirat Shah, Christy L Osgood, Anup K Amatya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2024
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract CancerSandra J Casak, Vaibhav Kumar, Chi Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
FDA Approval Summary: Tarlatamab for the Treatment of Extensive Stage Small Cell Lung CancerYufan Liu, Jeannette Nashed, Amy K Barone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2024
Improving Collection and Analysis of Overall Survival DataLisa R Rodriguez, Nicole J Gormley, Ruixiao Lu, et al.
The Oncologist|July 6, 2024
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutationsGautam U Mehta, Paz J Vellanki, Yi Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2023
FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade GliomaMichael I Barbato, Jeannette Nashed, Diana Bradford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2021
Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case ExamplesAnup K Amatya, Mallorie H Fiero, Erik W Bloomquist, et al.
Pageof 2